MedPal AI (MPAL) has launched New Health, a dedicated consumer sub-brand focused on the fast-growing GLP-1 weight management and broader peptide medicines market, backed by a £1.3 million national marketing campaign. The company said the launch is designed to sharpen its position in the competitive private weight-loss market ahead of a potential UK approval for Novo Nordisk’s oral weight-management pill later this year.
New Health will operate separately from MedPal AI’s broader clinic and consumer platform, acting as a specialist front-end brand while continuing to use the company’s existing regulated healthcare infrastructure, including AI-assisted intake, clinician assessments, pharmacy dispensing and patient monitoring.
The marketing campaign will run over six months, with digital channels expected to be a key focus as MedPal seeks to drive traffic to its new consumer websites and grow recurring patient numbers. Management said performance will be tracked closely across consultation volumes, conversion rates, customer acquisition costs and retention, allowing spend to be adjusted depending on commercial returns and clinical capacity.
Meanwhile, the company pointed to strong sector tailwinds, citing forecasts for rapid growth in UK prescription weight-loss medicines and the possibility that oral GLP-1 treatments could broaden demand by attracting patients reluctant to use injectable therapies. MedPal added that New Health will be supported by its existing NHS-contracted dispensing hubs and supply agreements with Eli Lilly and Novo Nordisk.
MedPal AI’s Founder and Chief Executive Officer Jason Drummond said: “New Health is a focused sub-brand within MedPal AI for a specific opportunity: GLP-1 weight management and the broader peptides category. This market is highly competitive and brand-led, so we need a consumer proposition that can compete on the same terms - a simple brand, a clear message, a dedicated funnel and strong clinical governance behind it.
“MedPal AI remains the operating system for personal health. New Health is the specialist point of access for patients seeking GLP-1 weight-management support and, over time, broader peptide-led healthcare services where clinically appropriate. The patient sees a clear consumer brand; behind it sits MedPal's AI-assisted intake, clinicians, prescribing pathway, pharmacy fulfilment and monitoring.”
A related party transaction was also disclosed, with Drummond licensing the new.co.uk and new.uk domain names to the company at no cost for an initial six-month period, after which MedPal will have the option to acquire them.
View from Vox
MedPal AI is making a clear commercial bet on one of digital healthcare’s fastest-growing segments. By creating a dedicated consumer brand rather than relying solely on its broader platform, the company is trying to compete more directly with specialist weight-loss providers while leveraging infrastructure it already owns. The key test now will be whether the £1.3 million marketing spend can convert efficiently into recurring patients.